Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

Mario Sabatelli, A Chiò, G Borghero, A Calvo, M Capasso, C Caponnetto, M Corbo, F Giannini, G Logroscino, J Mandrioli, N Marcello, L Mazzini, C Moglia, Mr Monsurrò, G Mora, F Patti, V Pietrini, F Pisano, E Pupillo, F SalviV Silani, Il Simone, G Sorarù, Mr Tola, P Volanti, E Beghi, M. Perini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

75 Citazioni (Scopus)

Abstract

A neuroprotective effect of lithium in amyotrophic lateral sclerosis (ALS) has been recently reported. We performed a multicenter trial with lithium carbonate to assess its tolerability, safety, and efficacy in patients with ALS, comparing 2 different target blood levels (0.4-0.8 mEq/L, therapeutic group [TG], vs 0.2-0.4 mEq/L, subtherapeutic group [STG]).
Lingua originaleEnglish
pagine (da-a)619-625
Numero di pagine7
RivistaNeurology
Volume75
DOI
Stato di pubblicazionePubblicato - 2010

Keywords

  • Adolescent
  • Adult
  • Aged
  • Amyotrophic Lateral Sclerosis
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Lithium Carbonate
  • Male
  • Middle Aged
  • Retrospective Studies
  • Single-Blind Method
  • Time Factors
  • Treatment Outcome
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial'. Insieme formano una fingerprint unica.

Cita questo